Related Experiment Video

Updated: Jul 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Perspectives for targeted therapies in cancer of unknown primary site

George Pentheroudakis1, Nicholas Pavlidis

  • 1Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 45110 Ioannina, Greece.

Cancer Treatment Reviews
|October 19, 2006
PubMed

Insights

Cancer of unknown primary site (CUP) is a deadly cancer. Gene and protein profiling reveals potential molecular targets for new therapies to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer of unknown primary site (CUP) is a significant cause of cancer mortality.
  • CUP is characterized by primary tumor regression, early metastasis, and treatment resistance.
  • Identifying molecular targets is crucial for developing effective targeted therapies for CUP.

Purpose of the Study:

  • To review gene and protein profiling studies in CUP.
  • To discuss the therapeutic potential of targeted agents based on identified molecular targets.
  • To explore the role of oncogenes, tumor suppressors, and angiogenesis effectors in CUP.

Main Methods:

  • Review of gene and protein profiling studies.
  • Analysis of expression data for oncogenes, tumor suppressor genes, and angiogenesis factors.
  • Discussion of targeted therapy agents.

Main Results:

  • CUP shows occasional Ras and BCL2 oncoprotein overexpression.
  • EGFR/c-KIT/PDGFR signaling is often inactive in CUP.
  • Tumor-suppressor gene mutations are uncommon, but angiogenesis is highly active.
  • Gene and protein profiling platforms offer insights into CUP's molecular landscape.

Conclusions:

  • Targeted therapy holds promise for CUP, but requires identification of specific molecular dependencies.
  • High-throughput multi-gene and multi-protein platforms are essential for understanding CUP's complex molecular pathophysiology.
  • Further research into molecular targets could lead to improved treatment strategies and outcomes for CUP patients.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...